

Ref: EPL/CS/SE/0025/2024

Date: November 08, 2024

To,

<b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	<b>BSE Limited</b> P J Towers, Dalal Street, Mumbai- 400 001
<b>Script Symbol: EMCURE</b>	<b>Scrip Code/Symbol: 544210/ EMCURE</b>

**Subject: Newspaper Publication of Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2024**

Dear Sir/Madam,

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith extracts of the Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2024, as published in the newspapers viz. "Financial Express" and "Loksatta" on November 08, 2024.

The above-mentioned extracts of Newspaper Publication are also being uploaded on the website of the Company i.e. <https://www.emcure.com>.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

**Chetan Sharma**  
**Company Secretary & Compliance Officer**  
**Membership Number: F8352**

## **Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

# Emcure<sup>®</sup>

## EMCURE PHARMACEUTICALS LIMITED

Registered and Corporate Office: Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune - 411 057, Maharashtra, India.

Tel: +91 20 3507 0033, +91 20 3507 0000; E-mail: investors@emcure.com; Website: www.emcure.com

Corporate Identity Number: L24231PN1981PLC024251

### EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2024

(₹ in Million)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30-Sep-24	30-Jun-24	30-Sep-23	30-Sep-24	30-Sep-23	31-Mar-24
1	Total Revenue from operations	20,019.84	18,151.38	16,630.89	38,171.22	32,192.51	66,582.51
2	Net Profit before tax	2,734.10	2,074.07	1,980.25	4,808.17	3,893.66	7,272.28
3	Net Profit after tax	2,015.49	1,525.90	1,458.36	3,541.39	2,868.01	5,275.75
4	Total Comprehensive Income	2,645.11	1,509.92	1,156.96	4,155.03	2,827.39	5,432.03
5	Paid-up equity share capital [Face value per share: ₹10]	1,890.98	1,811.52	1,808.52	1,890.98	1,808.52	1,811.52
6	Other equity (as shown in the audited Balance Sheet)						27,711.31
7	Earnings per share (not annualised for the Quarter and half year ended):						
	Basic (in ₹)	10.33	7.95	7.70	18.33	14.91	27.54
	Diluted (in ₹)	10.33	7.95	7.70	18.33	14.91	27.54

The key information of the Standalone Financial Results of the Company are given below:

(₹ in Million)

Sr. No.	Particulars	Quarter ended			Half year ended		Year Ended
		30-Sep-24	30-Jun-24	30-Sep-23	30-Sep-24	30-Sep-23	31-Mar-24
1	Total Revenue from operations	11,046.30	9,702.93	8,879.94	20,749.23	17,249.52	34,976.55
2	Net Profit before tax	1,193.58	550.48	358.91	1,744.06	837.64	1,999.12
3	Net Profit after tax	869.21	404.46	273.35	1,273.67	635.57	1,608.34
4	Total Comprehensive Income	868.46	402.22	258.29	1,270.68	620.51	1,554.95

#### Notes:

- The above Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 07, 2024.
- The above is an extract of the detailed format of the Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these Financial Results are available on the Stock Exchange websites, www.bseindia.com and www.nseindia.com and on the Company's website www.emcure.com.

For EMCURE PHARMACEUTICALS LIMITED

Sd/-

Satish Mehta

Managing Director & CEO

DIN: 00118691

Place: Pune

Date: 07 November, 2024

# Emcure®

## EMCURE PHARMACEUTICALS LIMITED

Registered and Corporate Office: Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune - 411 057, Maharashtra, India.  
 Tel: +91 20 3507 0033, +91 20 3507 0000; E-mail: investors@emcure.com; Website: www.emcure.com  
 Corporate Identity Number: L24231PN1981PLC024251

### EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2024

(₹ in Million)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30-Sep-24	30-Jun-24	30-Sep-23	30-Sep-24	30-Sep-23	31-Mar-24
1	Total Revenue from operations	20,019.84	18,151.38	16,630.89	38,171.22	32,192.51	66,582.51
2	Net Profit before tax	2,734.10	2,074.07	1,980.25	4,808.17	3,893.66	7,272.28
3	Net Profit after tax	2,015.49	1,525.90	1,458.36	3,541.39	2,868.01	5,275.75
4	Total Comprehensive Income	2,645.11	1,509.92	1,156.96	4,155.03	2,827.39	5,432.03
5	Paid-up equity share capital [Face value per share: ₹10]	1,890.98	1,811.52	1,808.52	1,890.98	1,808.52	1,811.52
6	Other equity (as shown in the audited Balance Sheet)						27,711.31
7	Earnings per share (not annualised for the Quarter and half year ended):						
	Basic (in ₹)	10.33	7.95	7.70	18.33	14.91	27.54
	Diluted (in ₹)	10.33	7.95	7.70	18.33	14.91	27.54

The key information of the Standalone Financial Results of the Company are given below:

(₹ in Million)

Sr. No.	Particulars	Quarter ended			Half year ended		Year Ended
		30-Sep-24	30-Jun-24	30-Sep-23	30-Sep-24	30-Sep-23	31-Mar-24
1	Total Revenue from operations	11,046.30	9,702.93	8,879.94	20,749.23	17,249.52	34,976.55
2	Net Profit before tax	1,193.58	550.48	358.91	1,744.06	837.64	1,999.12
3	Net Profit after tax	889.21	404.46	273.35	1,273.67	635.57	1,608.34
4	Total Comprehensive Income	888.46	402.22	258.29	1,270.68	620.51	1,554.95

#### Notes:

- The above Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 07, 2024.
- The above is an extract of the detailed format of the Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these Financial Results are available on the Stock Exchange websites, www.bseindia.com and www.nseindia.com and on the Company's website www.emcure.com.

For EMCURE PHARMACEUTICALS LIMITED  
Sd/-

Satish Mehta

Managing Director & CEO  
DIN: 00118691

Place: Pune  
Date: 07 November, 2024